- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Societal Cost of Obesity Could Reach $1.1 Trillion
If all 12.7 million US youth with obesity become obese adults, the individual cost on average is just over $92,000, and the societal costs over their lifetimes may exceed $1.1 trillion, according to findings from the Brookings Institute.
"The lifetime costs of obesity are sobering to say the least," said University of California System President Janet Napolitano at an event today to discuss new research that quantifies the economic costs of obesity in the US.
Ms Napolitano—former US secretary of homeland security and former governor of Arizona—addressed findings from the Center on Social and Economic Dynamics at Brookings, in partnership with the World Food Center of the University of California-Davis, that estimate that if all 12.7 million US youth with obesity become obese adults, the individual cost on average is just over $92,000, and "the societal costs over their lifetimes may exceed $1.1 trillion."
Read more at Brookings: http://brook.gs/1AWWlDi
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
